Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with
entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa
Decarboxylase Inhibitor (DDCI), in patients with Parkinson's Disease (PD) and end-of-dose
motor fluctuations.